Article in ACS chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Tim AguirreDepartment of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Street 2, 12489 Berlin, Germany.ORCID 0000-0003-3344-5877
Ellen TeichmannDepartment of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Street 2, 12489 Berlin, Germany.ORCID 0000-0002-4301-1530
Florian Q RömppDepartment of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Street 2, 12489 Berlin, Germany.
Ruthey VivierVA Portland Healthcare System, Portland, 97239 Oregon, United States.
Cole BryantVA Portland Healthcare System, Portland, 97239 Oregon, United States.
Matthew A HulversonDivision of Allergy and Infectious Diseases, Center for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, University of Washington, 750 Republican Street, P.O. Box 358061, Seattle, 98109 Washington, United States.ORCID 0000-0002-3413-4969
Wesley C Van VoorhisDivision of Allergy and Infectious Diseases, Center for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, University of Washington, 750 Republican Street, P.O. Box 358061, Seattle, 98109 Washington, United States.ORCID 0000-0001-6141-2015
Kayode K OjoDivision of Allergy and Infectious Diseases, Center for Emerging and Re-emerging Infectious Diseases (CERID), Department of Medicine, University of Washington, 750 Republican Street, P.O. Box 358061, Seattle, 98109 Washington, United States.
J Stone DoggettVA Portland Healthcare System, Portland, 97239 Oregon, United States.ORCID 0000-0002-6098-1520
Dorothea FiedlerDepartment of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Street 2, 12489 Berlin, Germany.ORCID 0000-0002-0798-946X
Stefan HechtDepartment of Chemistry, Humboldt-Universität zu Berlin, Brook-Taylor-Street 2, 12489 Berlin, Germany.ORCID 0000-0002-6124-0222
Funding
Optimization of Lead BKIs for Cryptosporidiosis TherapyR01AI155412 · NIAID · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2021 to 2025
$4.1M
Bumped-Kinase Inhibitor Drug Development for ToxoplasmosisR01HD102487 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2021 to 2025
$3.3M
Development of Dual Efficacy Therapeutic Against Cryptosporidiosis and GiardiasisR21AI140881 · NIAID · UNIVERSITY OF WASHINGTON · PI OJO, KAYODE K · 2019 to 2020
Potent and selective small-molecule inhibitors are valuable tools to elucidate the functions of protein kinases within complex signaling networks. Incorporation of a photoswitchable moiety into the inhibitor scaffold offers the opportunity to steer inhibitor potency with temporal precision, while the challenge of selective inhibition can often be addressed by employing a chemical genetic approach, termed the analog-sensitive method. Here, we combine the perks of these two approaches and report photoswitchable azopyrazoles to target calcium-dependent protein kinase 1 (CDPK1) from
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Photoswitchable Inhibitors to Optically Control Specific Kinase Activity. · full record | OpenQuestion